Antech acquires Canadian biotech company

The deal brings Antech’s RenalTech predictive diagnostic tool north of the border

Antech Diagnostics has strengthened its laboratory services in Canada with the purchase of Quebec-based biotechnology company, Biovet.

The acquisition, Antech says, adds extensive R&D assets to the company’s offerings and supports its goal of driving diagnostic advancements in animal health.

“We’re very pleased to welcome Biovet’s employees and customers to the Antech family,” says Antech’s chief operating officer (COO), Mary Kurian. “Biovet’s expertise in food and companion animal diagnostics both complements and enhances Antech’s strengths, accelerating our ability to expand services to veterinarians across North America. Biovet’s rich R&D pipeline will enhance our own, which translates to innovative new products and services that help veterinarians keep pets healthy.”

Founded in 1991, Biovet operates a United States Department of Agriculture- (USDA-) and Canadian Food Inspection Agency- (CFIA-) certified laboratory, which serves veterinarians across Canada.

Under the terms of the agreement, Biovet will continue to provide clients with reference laboratory services. Additionally, it will offer expanded access to innovative diagnostics, including Antech’s new predictive diagnostic tool, RenalTech, which can indicate the onset of chronic kidney disease in cats two years before onset.

Biovet president and CEO, René Lallier, DVM, MBA, will continue to lead the company’s operations as general manager, overseeing its team of scientists and laboratory service professionals.

“For nearly three decades, Biovet has led Canada in high-quality laboratory services and diagnostic innovation,” Dr. Lallier says. “Joining with Antech is a natural blend of two like-minded organizations with a shared commitment to delivering innovation and quality to veterinarians, allowing them to deliver excellent, compassionate care to pets.”

Comments
Post a Comment

Comments